Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

To cite this version:

HAL Id: hal-03733979
https://hal-cnam.archives-ouvertes.fr/hal-03733979
Submitted on 21 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives| 4.0 International License
Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Emmanuelle Jeannot1,2, Aurélien Latouche3,4, Claire Bonneau3,5, Marie-Ange Calméjane1, Corine Beaufort3, Kirsten Ruigrok-Ritsstier6, Guillaume Bataillon1, Linda Larbi Chériif2, Céïlia Dupain7, Charlotte Lecerf7, Marina Popovic8, Anne de la Rochefordière9, Fabrice Lecuru5, Virginie Fourchotte5, Ekaterina S. Jordanova10, Heiko von der Leyen11, Carine Tran-Perennou1, Marie-Emmanuelle Legrier12, Sylvain Dureau12, Laurence Raizonville12, Diana Bello Roufai7, Christophe Le Tourneau3,7,13, Ivan Biene4, Roman Rouzier3,5, Els M.J.J Berns6, Maud Kamal7, and Suzy Scholl7

ABSTRACT

Purpose: Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period.

Experimental Design: We analyzed serum samples from 94 HPV16- or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV E7 gene as a marker for residual disease compared to HPV integration site and PIK3CA mutations. Finally, the prognostic impact of circulating HPV E7 gene was assessed with its prediction value of relapse.

Introduction

Human papillomavirus (HPV) infection is the etiologic agent of almost all cervical cancers, the second leading cause of gynecologic cancer–related death in women worldwide (1, 2). Standard treatment consists of surgery for early-stage disease (stage FIGO ≤ IB2), while chemoradiation is recommended for patients with locally advanced disease (stage FIGO IB3–IIIC/IVA). For locally advanced stages, salvage hysterectomy for suspected residual disease after chemoradiation has been extensively debated. While it improves local control of the tumor, it remains associated with increased morbidity and no impact on improved overall survival was ever documented (3, 4). Salvage hysterectomy after full dose radiotherapy is therefore usually limited to patients with a very high suspicion for residual tumor. However, these patients with high risk of developing local relapse or distant metastases are not easily identifiable as their monitoring remains complex. Radiologic imaging results can be difficult to appreciate and pathologic reports of biopsies may document fibrosis and inflammation, leaving an uncertainty as to whether there are still viable tumor cells (5).

The detection of circulating tumor DNA (ctDNA), a fraction of cell-free circulating DNA released from tumor cells into the bloodstream, is now widely used for monitoring disease in various tumor types (6–8). Somatic mutations may thus serve as ctDNA markers and are commonly detected by digital PCR or NGS techniques (9–11). In patients with HPV-related tumors, circulating HPV DNA (HPV ctDNA) may be similarly detected in blood, either in episomal form or integrated into tumor DNA (12–16). Furthermore, HPV appears to be a stable tumor marker over time, because the same HPV type identified in a primary tumor is also observed in metastatic tissue (17). The clinical value of HPV ctDNA has already been investigated in patients with HPV-related tumors (17–20). While we previously reported on the use of HPV ctDNA for monitoring the efficacy of immunotherapy or chemotherapy in metastatic anal cancer (21, 22), its use as a predictive and prognostic biomarker has recently been more...
Serum, we also assessed viral early prediction of relapse after primary treatment in cervical cancer, objective was to investigate whether HPV ctDNA may be used for the identify molecular patterns associated with poor outcome.

In the current study, we observed that HPV ctDNA can be detected before treatment by droplet-digital PCR (ddPCR) in a high proportion of patients with advanced stage (71% of stages III and IV) and persistence of HPV ctDNA after first-line therapy predicted relapse of cervical cancer.

The short turnaround time, high sensitivity, and limited cost of the detection of HPV ctDNA by ddPCR are compatible with clinical practice. This opens the possibility of monitoring patients with cervical cancer and identifying patients with high risk to relapse, allowing studies to evaluate the benefit of salvage surgery or innovative drug combinations for patients with residual HPV ctDNA after treatment.

and more reported by others, both in anal and head and neck cancers (23–25), as well as in a small prospective cohort of cervical cancer (26) and in a small retrospective cohort of metastatic cervical cancer (12).

In the current study from the European prospectively collected BioRAIDs (NCT02428842) cervical cancer dataset (27–31), the main objective was to investigate whether HPV ctDNA may be used for the early prediction of relapse after primary treatment in cervical cancer, similarly to other HPV-related cancers. Beyond HPV E7 detection in serum, we also assessed viral–cellular DNA junction sequences resulting from HPV integration into the tumor genome, together with PIK3CA mutations, a somatic marker of high prevalence in cervical cancer.

Materials and Methods

Patients and samples

The European funded RAIDs Network (Rational Molecular Assessment and Innovative Drug Selection, www.raids-fp7.eu) prospectively monitored the multicenter trial BioRAIDs (NCT02428842), with the objectives to generate high quality samples and molecular assessments to stratify patient populations with cervical cancer and to identify molecular patterns associated with poor outcome.

Detailed eligibility criteria and treatments have been previously reported elsewhere (28, 29). Main eligibility criteria were: patients with stage IB2–IV disease (2018 FIGO staging system); all histologic subtypes (excluding neuro-endocrine type); no prior treatment for cervical cancer; signed informed consent. The patients \( n \) (n = 419) included in the study received standard treatment, according to the standards of each center.

The study was approved by the respective local ethics committees: Comité pour la protection des personnes (CPP) Ile de France in France, The Serbian Medical Society Belgrade in Serbia, The Protocol Toetsingscommissie of the Antoni van Leeuwenhoek (PTC) in the Netherlands, The Medizinische Hochschule Hannover Ethik-kommission in Germany, The National Ethics Committee of Health Ministry of Republic of Moldova, Academy of Medical Sciences National Ethics Committee for medicines and medical devices in Romania. The study was conducted according to national requirements and the guidelines of the Declaration of Helsinki.

Tumor samples were collected at baseline before treatment and cryopreserved for molecular analysis. All samples were histologically reviewed at the time they were included into HPV testing. Only tumor samples with at least 30% of tumor cells were selected for the study.

Serum samples were collected at inclusion, at the end of treatment and during follow-up visits at 6, 12, and 18 months. Imaging was performed before treatment for all patients. Depending on the center, additional imaging may be available at the end of treatment and the follow-up visits.

The current study focused on serum samples from 94 patients, selected for HPV16- or HPV18-positive CC, according to the workflow presented in the Fig. 1. Serum samples taken, at range 28 days before and 120 days after the date of the end of treatment (EOT), and 120 days before relapse, were considered as EOT samples.

HPV typing and integration site

HPV typing was previously performed as described previously (30), using the SPF10 primer set Inno-LIPA HPV genotyping extra line probe assay (Fujirebio Europe) according to the manufacturer’s protocol. Among the 94 HPV16/18–related cases, 2 squamous cell carcinomas (SCC) and 2 adenocarcinomas were initially identified carrying multiple infections using INNO-LIPA in FFPE samples. One SCC case and 2 adenocarcinoma cases related to HPV16 and HPV18, while the other SCC case was associated with HPV16 and HPV73. However, HPV typing by ddPCR in DNA from frozen tumor confirmed only one HPV type among the three cases initially characterized as HPV16- and HPV18-related. Hence, these 3 cases were considered single-type for further study.

For the 23 patients with an HPV integration site into tumor DNA previously identified by the Capture-HPV method followed by NGS (27), we designed digital droplet PCR (ddPCR) assays to specifically amplify the viral-cellular DNA junction sequences. Primer and probe sequences are listed in the Supplementary Table S1.

HPV ctDNA quantification

Serum samples were stored at −80°C until DNA isolation. Circulating cell-free DNA (cfDNA) was isolated in duplicate from 200 μL of serum using the QIAamp Min Elute Virus Spin Kit (Qiagen), according to the manufacturer’s instructions. Elution was performed in 25 μL of supplied elution buffer; eluates from the same sample were pooled and stored at −20°C until HPV ctDNA analysis.

ddPCR reactions were performed using the QX100 system (Bio-Rad Laboratories) according to the manufacturer’s protocol. Briefly, 20 μL of MasterMix solution was prepared, containing 10 μL of 2 × ddPCR SuperMix for probes without dUTP (Bio-Rad), relevant primers at 450 nmol/L each and relevant TaqMan probes at 250 nmol/L each (Applied Biosystems), DNA template (6 μL), and nuclease-free water. PCR reactions were run on a C1000 thermal cycler (Bio-Rad) using the following program: 95°C 1 minute, 40 cycles of (94°C 30 seconds, 60°C 1 minute) 98°C 10 minutes. The concentration of HPV DNA copies was estimated with the QuantaSoft v1.7.4 software.

Three replicates were performed to detect HPV16, HPV18, or HPV integration site using HPV16 E7, HPV18 E7, or viral–cellular junction specific primers and TaqMan probes (Supplementary Table S1), multiplexed with a commercial human ddPCR assay targeting RPP30 gene (dHSaCP2500350, Bio-Rad Laboratories), used as human DNA reference. For each patient, genomic DNA from frozen tumor was tested as positive control and a triplicate of no DNA was tested for each plate.

According to our previous findings, serum samples were considered HPV-positive in presence of at least three droplets containing HPV amplicons. A sample was considered HPV-negative when fewer than 3
or no droplets containing HPV amplicons were detected, while more than 500 copies/mL were detected for RPP30 human reference gene. Finally, HPV ctDNA concentration was expressed in copies/mL of serum.

**PIK3CA mutation detection**

PIK3CA mutation screening in tumor tissue was performed by paired-end whole exome sequencing and paired-end targeted gene panel sequencing as previously described (30).

Serum samples used for PIK3CA analysis were from the same aliquots used for HPV analysis. Circulating cell-free DNA (cfDNA) was isolated from 1 to 2 mL serum with the QIAamp Circulating Nucleic Acid kit (Qiagen) according to the manufacturer’s manual. This cfDNA was isolated into 20 µL elution buffer. PIK3CA ctDNA analysis was performed with TaqMan p.E542K, p.E545K, and p.H1047R-specific assays and the QuantStudio 3D Digital PCR system (Thermo Fisher Scientific) according to the manufacturer’s specifications. Reaction mixtures, including serum DNA and QuantStudio 3D Digital PCR Master Mix, were loaded on digital PCR chips with 20,000 wells, and cycled under standard conditions: 96°C for 10 minutes, 40 cycles of (60°C 2 minutes, 98°C 30 seconds). QuantStudio 3D analysisSuite determined the proportion of mutant and wild-type templates, and details are given in article by Vitale and colleagues (32).

**Tumoral HPV copy number**

HPV copy number in tumor cells was determined by ddPCR, using the same specific HPV and RPP30 assays as in HPV ctDNA quantification experiment. Experiments were performed with 5 ng of tumor DNA isolated from frozen tissues, in duplicates for each sample. The RPP30 gene was used as a reference for two copies of DNA sequences per cell. The value retained as corresponding to HPV copy number in tumor cells was twice that of the ratio HPV E7/RPP30 provided by the ddPCR experiment.

**Statistical analysis**

This report was written in accordance with REMARK criteria (33). For this study, no prespecified power was calculated. Fisher exact test was used for categorical variables and Spearman correlation test was used for continuous variables. Wilcoxon matched pairs signed rank test was used to compare HPV E7 ctDNA levels, HPV integration sites, and PIK3CA assays. Survival curves were compared with the use of an unstratified log-rank test, and HR with 95% confidence interval (CI) was calculated using a univariable and a multivariable Cox model including clinical characteristics such as age, FIGO stage, lymph node involvement, and HPV type. Progression-free survival (PFS) was defined as the time from the start of treatment to tumor recurrence or death. Statistical analyses and figures were performed using GraphPad Prism software version v-6–07 (GraphPad software) and R.
software version 4.0.2. All statistical tests were two-tailed, and P values < 0.05 were considered statistically significant.

Access to data
All data are available upon request.

Results
Patient characteristics
Ninety-four patients, from the BioRAIDs European study, with a documented HPV16- or HPV18-related tumor were included in the present study. The clinical and biological characteristics as well as their association with detectable HPV ctDNA before treatment are presented in Table 1 and Supplementary Table S2. Briefly, the median age of the patients was 50 years (range, 24–80); the main histologic tumor type was SCC (87%). HPV16 was detected in 81% of the tumors. Almost three quarters of the patients (73%) presented with a FIGO stage III or IV tumor type. Sixty-two patients (66%) had positive lymph nodes (by pathology and/or NMR imaging), predominantly in the pelvis (64%). Most patients (65%) were treated by first line chemoradiation, 20% underwent primary surgery and 15% received neoadjuvant chemotherapy (Table 1). Median follow-up was 16.7 months and 41% (39/94) patients relapsed during the planned 18-month follow-up period.

Serum had been routinely collected at baseline for all patients (Fig. 1). Additional serum samples collected after treatment were available in 72 patients (77%). Among them, 40 patients had a serum sample taken at the end of treatment and 44 patients had at least one serum sample collected during surveillance (Fig. 1). In 6 patients, serum samples were available at the time of relapse. In this cohort of 94 CC, HPV integration sites and PIK3CA mutations had been previously identified in the tumor tissue of 23 and 27 patients respectively (Fig. 1). Patient characteristics of both subgroups are detailed in Supplementary Table S3.

HPV ctDNA detection before treatment
Using E7 gene sequence probes, HPV ctDNA was successfully detected before treatment in serum samples of 63% (59/94) patients (Table 1). The median level of HPV ctDNA was 42 copies/mL serum (range, 0–353,750) in the whole cohort, while the median level of the housekeeping gene, RPP30, was 23,355 copies/mL serum (range, 667–514,167; Supplementary Fig. S1). Among the 59 patients with detectable HPV ctDNA, the median level was 263 copies/mL serum with an interquartile range (IQR) of 53–2,916. There was a positive significant association between the detection of HPV ctDNA and tumor stage (HPV ctDNA detection in 42% (11/26) of stage I–II versus 70% (48/68) of stage III–IV; P = 0.02, Fisher test) and histologically proven para-aortic lymph node involvement [HPV ctDNA detection in

Table 1. Patient clinical and biological characteristics and comparison between patients with detectable versus undetectable HPV ctDNA.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>All patients</th>
<th>Detectable HPV ctDNA at baseline</th>
<th>Undetectable HPV ctDNA at baseline</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n = 94</td>
<td>n = 59</td>
<td>n = 35</td>
<td></td>
</tr>
<tr>
<td>Age (in years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>50 (24–80)</td>
<td>50 (24–80)</td>
<td>51 (24–78)</td>
<td></td>
</tr>
<tr>
<td>FIGO stage (2018)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>9 (9%)</td>
<td>4 (7%)</td>
<td>5 (14%)</td>
<td>0.02</td>
</tr>
<tr>
<td>II</td>
<td>17 (18%)</td>
<td>7 (12%)</td>
<td>10 (29%)</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>58 (62%)</td>
<td>39 (66%)</td>
<td>19 (54%)</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>10 (11%)</td>
<td>9 (15%)</td>
<td>1 (3%)</td>
<td></td>
</tr>
<tr>
<td>Lymph node</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(N0)</td>
<td>32 (34%)</td>
<td>16 (27%)</td>
<td>16 (46%)</td>
<td>0.08</td>
</tr>
<tr>
<td>(N+)</td>
<td>62 (66%)</td>
<td>43 (73%)</td>
<td>19 (54%)</td>
<td></td>
</tr>
<tr>
<td>Para-aortic lymph node</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(N0)</td>
<td>72 (77%)</td>
<td>40 (68%)</td>
<td>32 (91%)</td>
<td>0.01</td>
</tr>
<tr>
<td>(N+)</td>
<td>22 (23%)</td>
<td>19 (32%)</td>
<td>3 (9%)</td>
<td></td>
</tr>
<tr>
<td>Pelvic lymph node</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(N0)</td>
<td>34 (36%)</td>
<td>18 (31%)</td>
<td>16 (46%)</td>
<td>0.18</td>
</tr>
<tr>
<td>(N+)</td>
<td>60 (64%)</td>
<td>41 (69%)</td>
<td>19 (54%)</td>
<td></td>
</tr>
<tr>
<td>Histology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCC</td>
<td>82 (87%)</td>
<td>52 (88%)</td>
<td>30 (86%)</td>
<td>0.76</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>10 (11%)</td>
<td>6 (10%)</td>
<td>4 (11%)</td>
<td></td>
</tr>
<tr>
<td>ASC</td>
<td>2 (2%)</td>
<td>1 (2%)</td>
<td>1 (3%)</td>
<td></td>
</tr>
<tr>
<td>HPV type</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV16</td>
<td>76 (81%)</td>
<td>47 (80%)</td>
<td>29 (83%)</td>
<td>0.79</td>
</tr>
<tr>
<td>HPV18</td>
<td>18 (19%)</td>
<td>12 (20%)</td>
<td>6 (17%)</td>
<td></td>
</tr>
<tr>
<td>HPV copy number</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5 copies/cell</td>
<td>32 (34%)</td>
<td>13 (22%)</td>
<td>19 (64%)</td>
<td>0.003</td>
</tr>
<tr>
<td>≥5 copies/cell</td>
<td>62 (66%)</td>
<td>46 (78%)</td>
<td>16 (46%)</td>
<td></td>
</tr>
<tr>
<td>Initial treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery</td>
<td>19 (20%)</td>
<td>9 (15%)</td>
<td>10 (28%)</td>
<td></td>
</tr>
<tr>
<td>Chemoradiotherapy</td>
<td>61 (65%)</td>
<td>39 (66%)</td>
<td>22 (63%)</td>
<td></td>
</tr>
<tr>
<td>Neo-chemotherapy</td>
<td>14 (15%)</td>
<td>11 (19%)</td>
<td>3 (9%)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ADK, adenocarcinoma; ASC, adenosquamous carcinoma; P, Fisher test; SCC, squamous cell carcinoma.
56% (40/72) of node negative versus 86% (19/22) of node positive, \( P = 0.01, \) Fisher test; Table 1; Fig. 2A. In addition, we observed a positive correlation between serum HPV ctDNA level and HPV copy number (\( R = 0.39, P < 0.001, \) Spearman; Fig. 2B). There was no significant association between the detection of HPV ctDNA and other clinical characteristics such as patient age, histology, or HPV type.

ctDNA detection by HPV integration site and PIK3CA mutation

Furthermore, in the serum samples of a subgroup of 23 patients, the detection rates of HPV E7 gene and HPV integration site were compared. The results showed that the HPV integration site was a significantly less sensitive ctDNA marker than serum HPV E7 (\( P = 0.001, \) Wilcoxon matched pair signed rank test), with a detection rate of 39% (9/23), while HPV E7 detection rate reached 70% (16/23; Fig. 2C). Finally, the detection rates of HPV E7 and PIK3CA mutations were compared in serum samples from the 27 patients harboring a PIK3CA mutation in their tumor. HPV E7 detection was significantly more sensitive than PIK3CA mutation (\( P < 0.001 \) Wilcoxon matched pair signed rank test) with detection rates of 52% (14/27) and 30% (8/27), respectively (Fig. 2D).

Prognostic value of persistent HPV E7 detection in serum at end of treatment

In the sequel, we defined the binary covariate HPV ctDNA detection with value 1 corresponding to HPV E7 positive and value 0 for undetectable HPV E7. Among the 94 patients, 40 experienced PFS. In a univariable Cox landmark regression model, HPV ctDNA detection at baseline was not associated with PFS (HR = 1.59; 95% CI, 0.79–3.20; \( P = 0.19; \) Fig. 3A). No significant association was observed with multivariable landmark analysis (HR = 1.08; 95% CI, 0.51–2.30; \( P = 0.841 \)).

To estimate the effect of HPV ctDNA detection at the end of the treatment, we used the landmark approach considering only patients at risk of PFS at the end of their treatment. In a univariable Cox landmark regression model, HPV ctDNA detection was associated with a short PFS (HR = 10.95; 95% CI, 2.94–40.7; \( P < 0.0001; \) Fig. 3B). Of note 81% (9/11) of the patients with a positive detection experienced a PFS. Multivariable landmark analysis also showed significant association between HPV ctDNA detection at the end of treatment and PFS (HR = 14.25; 95% CI, 3.10–61.57; \( P = 0.001 \)).

Diagnosis of relapse by persistence of HPV E7 in serum during follow-up

Forty-four of 94 patients had a longitudinal follow-up, among whom 16 patients (36%) did relapse during the follow-up period. Serum samples from patients with undetectable HPV ctDNA at end of treatment remained HPV negative during follow-up with one exception, patient #26 who presented a serum conversion at 14 months, remaining positive at 17 months (Fig. 4). There was no clinical sign of
recurrence at this last follow-up when the patient went off study and could not be traced thereafter. The negative predictive value of undetectable ctDNA for cervical cancer relapse was 95%.

Among the 11 patients with residual HPV ctDNA at end of treatment, 8 could be followed up longitudinally. HPV ctDNA remained detectable in 6 of 8 patients (75%) while there was no clinical sign of recurrence. All 6 patients (patients #3, #9, #10, #12, #14, and #15) relapsed eventually (Fig. 4). HPV ctDNA was detected on average 10 months before a clinical diagnosis of relapse (range, 2–15 months).

Serum samples at the time of relapse were available for 6 patients (patients #1, #4, #6, #9, #12, and #13), and HPV ctDNA was detected in 4 of 6 patients (patients #1, #9, #12, and #13). It is interesting to note that in these 4 patients, HPV ctDNA detection remained consistently positive throughout the follow-up, before and after treatment. Among these 4 patients, two (patients #1, #12) also harbored a somatic PIK3CA mutation, which became undetectable by the end of the treatment, contrary to HPV ctDNA (Fig. 5). The PIK3CA mutation in serum became detectable again at the time of relapse in both patients. In patient #12, the PIK3CA mutation was detected 6 months before clinical diagnosis of relapse.

![Figure 3](image3.png)

**Figure 3.** Progression-free survival of patients according to the positivity of HPV ctDNA detection. **A**, Before treatment (n = 94). **B**, At the end of treatment (n = 40).

**Discussion**

In this European prospective cohort of cervical cancers, we confirmed (i) that HPV E7 sequences are a sensitive marker to detect ctDNA, and (ii) that HPV ctDNA detection after treatment is strongly prognostic of an early recurrence.

Our 63% serum detection rate by ddPCR before treatment is consistent with previous studies that reported HPV detection rates of 56% to 100%, using HPV E7 gene primers in primary cervical cancers (14, 26, 34), or in other HPV-related cancers (14, 17, 18, 20).

HPV-related tumor cells usually contain many copies (up to hundreds) of the HPV genome, in episomal form as well as integrated into tumor DNA. Hence, the release of multiple HPV copies from dying tumor cells into the bloodstream, contributes to an increased sensitivity of the detection method compared with that of a single point mutation (one copy/tumor cell). In addition, HPV E7 ctDNA detection rate is also superior to that of HPV integration site (Fig. 2C) because it includes both the episomal and the integrated HPV (16, 27). This is consistent with another retrospective study of 21 serum samples showing a poor detection rate (33%) of HPV integration site when analyzed by NGS before tumor resection (15). Hence, our results prioritize ctDNA detection by using HPV E7 sequences as a predictive biomarker of relapse when compared with HPV integration site or PIK3CA point mutations (16, 27, 30). However, it is well-known that HPV integration site is unique for each tumor and can be considered as a highly specific tumor marker (35, 36). Depending on center resources, circulating HPV integration site screening may be performed and help for detection of relapse.

A main finding of the present prospective study is that patients with residual HPV ctDNA at the end of treatment have a high risk of relapse. Only 2 of 11 patients with a positive HPV ctDNA sample at the end of the treatment were able to clear the HPV ctDNA sequences in the following sample and did not relapse by the end of follow-up. Similar findings have recently been described in another study in HPV-associated oropharyngeal cancer (25). Transient residual HPV ctDNA after treatment was observed for a subgroup of patients who cleared HPV ctDNA in the following sample and did not relapse (follow-up up to 5 years), suggesting that 2 consecutive serum samples may be required to predict relapse after treatment (25).

The ability to anticipate the presence of residual/persistent diseases up to 15 months before a diagnosis of relapse has a high clinical value (3, 4). In particular, it may enable to propose a salvage surgery to patients by confirming the likelihood of residual pelvic disease after chemoradiation (37, 38). The early detection of persistent/recurrent disease is particularly important in irradiated tissues to minimize the radicality of the surgery which can go as far as total exenteration if the...
Figure 4.
HPV ctDNA dynamics from the EOT to the end of follow-up. Each line corresponds to a patient (n = 44); patients without relapse and with relapse are identified in blue (top of the figure) and red (bottom), respectively. The length of the lines (top) corresponds to the duration of follow-up. Red (○) and blue (●) correspond to HPV-positive and HPV-negative serum samples, respectively. Serum samples in dashed area correspond to EOT samples. Patients with HPV ctDNA in their EOT samples are indicated by a black arrow. Diagnosis of relapse corresponds to the end of the line. S1, serum sample before treatment; R, relapse.

Figure 5.
ctDNA dynamics according to HPV E7 (black line) and PIK3CA mutation (gray line).
recurrence invades neighboring organs. Similar conclusions were reported in head and neck cancers, the immediate posttreatment HPV ctDNA detection being helpful for the post-radiotherapy management of patients with HPV-related tumors (39, 40).

A new prospective clinical trial comparing the value of imaging versus repeated HPV serum detection by integrating sequential ddPCR would be useful to better define the role and the cost effectiveness of these tests. Because the prognosis of patients with detectable HPV ctDNA at the end of the chemoradiation is poor, this population may benefit from innovative drugs or maintenance therapy, in particular immunotherapy. Monitoring of HPV ctDNA could help future clinical trials to target a high-risk population.

The analysis was focused on patients with HPV16- and HPV18-related tumors, which represent approximately 70% of patients with cervical cancer. Further analyses, including patients with other HPV-type tumors would be useful. Moreover, because the cohort was led at a European level, it was not possible to pursue the follow-up beyond 18 months, as initially planned in the RAIDs consortium. For this reason, it was not possible to obtain additional information on patient (#26) with two consecutive HPV positive serum samples at the end of her follow-up period.

In conclusion, our study confirms that the HPV E7 gene is a sensitive and a suitable tumor marker for treatment monitoring and long-term follow-up of patients with cervical cancer. To our knowledge, this is the first large prospective study to show that detection of HPV ctDNA by ddPCR may predict relapse in cervical cancer at the end of first-line therapy. Further studies are needed to confirm the clinical value of HPV ctDNA for an early detection of residual disease/relapse and to evaluate the role/purpose of salvage surgery as compared with that of innovative drug combinations for patients with residual HPV ctDNA after treatment. Two studies, Circa HPV (NCT03739775) and the PEVO basket trial (NCT04357873), are actually ongoing and will allow a comparison between imaging and HPV ctDNA and evaluate its predictive value for relapse detection and for efficacy of innovative drug combination (41).

**Authors’ Disclosures**

M. Popovic reports grants from FP7 project Rational molecular Assessment and Innovative Drug Selection - RAIDs during the conduct of the study. H. von der Leyen reports grants from EU FP7 program: ‘PRIORITY’ during the conduct of the study. C. Le Tourneau reports personal fees from MSD, BMS, Merck Serono, Nanobiotix, Rakuten, Seattle Genetics, AstraZeneca, Roche, GSK, and Celgene outside the submitted work. M. Kamal reports grants from European commission and Agence de la Recherche Contre le Cancer during the conduct of the study; personal fees from F. Hoffmann-La Roche Ltd outside the submitted work. No disclosures were reported by the other authors.

**Authors’ Contributions**

E. Jeannot: Conceptualization, formal analysis, writing—original draft, writing—review and editing. A. Latouche: Formal analysis, methodology, writing—original draft, writing—review and editing. C. Bonneau: Writing—original draft, writing—review and editing, acquisition of data. M.-A. Calmès: Writing—original draft, writing—review and editing. K. Ruigrok-Rüstit: Writing—original draft, writing—review and editing, acquisition of data. C. Beaufort: Writing—original draft, writing—review and editing. A. Lari Chérif: Writing—original draft, writing—review and editing, acquisition of data. C. Dupain: Resources, writing—original draft, writing—review and editing, acquisition of data. C. Lecerf: Resources, writing—review and editing, acquisition of data. M. Popovic: Writing—original draft, writing—review and editing, acquisition of data. A. de la Rochebordère: Writing—original draft, writing—review and editing, acquisition of data. F. Lecuru: Writing—original draft, writing—review and editing, acquisition of data. V. Fourchotte: Writing—original draft, writing—review and editing. E.S. Jordanova: Writing—original draft, writing—review and editing, acquisition of data. M. Kamal: Formal analysis, supervision, writing—review and editing, acquisition of data. L. Raizounville: Resources, writing—original draft, writing—review and editing, acquisition of data. D. Bello Roufai: Writing—original draft, writing—review and editing, acquisition of data. H. von der Leyen: Writing—original draft, writing—review and editing, acquisition of data. C. Tran-Perennou: Writing—original draft, writing—review and editing. J. Bleche: Supervision, writing—original draft, writing—review and editing. R. Roussier: Supervision, writing—original draft, writing—review and editing. E.M.J.J. Berns: Supervision, writing—original draft, writing—review and editing. M. Legrier: Resources, writing—original draft, writing—review and editing, acquisition of data. S. Dureau: Resources, writing—original draft, writing—review and editing, acquisition of data. A. Latouche: Review and editing.

**Acknowledgments**


European Union’s Seventh Program for research, technological development and demonstration (agreement N° 304810), the Fondation ARC pour la recherche contre le Cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked ‘advertisement’ in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 16, 2021; revised April 22, 2021; accepted June 28, 2021; published first July 1, 2021.

**References**

HPV ctDNA for Relapse Detection in Cervical Cancer

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Emmanuelle Jeannot, Aurélien Latouche, Claire Bonneau, et al.

Clin Cancer Res  Published OnlineFirst July 1, 2021.

Updated version Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-21-0625

Supplementary Material Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2021/07/01/1078-0432.CCR-21-0625.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2021/10/07/1078-0432.CCR-21-0625. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.